September 16, 2025 – Imaging Biometrics, LLC (IB), a leading provider of advanced MRI analytics, is pleased to announce an agreement with MedImageMetric, LLC (MIM) to commercialize its patented quantitative susceptibility mapping (QSM) software, QSMetric™. QSMetric is available for immediate sale through IB as an annual license subscription.
FDA-cleared QSMetric is an advanced MRI technique that measures how tissue responds to magnetic fields – revealing subtle biochemical changes often missed by traditional imaging. It enables clinicians to quantify magnetic susceptibility changes in tissue – offering critical insights into iron deposition, microbleeds, demyelination calcification, and other markers of disease progression or treatment response. The automated software has clinical applications that span neurodegenerative diseases, multiple sclerosis, neurological and psychiatric disorders, cerebrovascular disease, traumatic brain injury, brain tumors, and more – providing the sensitivity and specificity needed for confident diagnosis.
“This agreement brings together MIM’s innovation and IB’s commercialization strength to accelerate access to a powerful, clinically validated imaging solution,” said Dr. Yi Wang, PhD, MIM’s President. “The fact that QSMetric is both FDA-cleared and patent-protected underscores its scientific rigor and commercial readiness.”
The collaboration also opens the door to joint development initiatives, including:
- Integration of QSMetric with IB’s solutions to enhance neuro characterization.
- Expansion into multi-parametric imaging workflows for neuro-oncology, neurodegeneration, and vascular disorders.
- Co-development of AI-driven analytics and clinical decision support tools leveraging QSMetric data.
A recent study published in Radiology demonstrated how QSM measures iron-related pathology, supporting its role in managing neurodegenerative diseases, particularly in predicting cognitive decline (Radiology, Sept 9, 2025). This positions QSMetric to support the growing demand for advanced imaging in Alzheimer’s care – a U.S. diagnostics market currently valued at over $3.5 billion. With the rise of FDA-approved anti-amyloid therapies, MRI-based monitoring for amyloid-related imaging abnormalities (ARIA) has become a clinical and regulatory priority. QSMetric’s ability to detect and quantify microhemorrhages and iron accumulation independent of imaging parameters (Radiology, Jan 1, 2012) offers a robust quantitative solution for ARIA-H surveillance—making it a valuable tool for memory clinics, imaging networks, and trial sponsors navigating this rapidly expanding market.
“QSMetric is a perfect complement to our portfolio of advanced imaging solutions,” added Michael Schmainda, IB’s CEO. “We’re excited to bring this technology to market and help clinicians unlock deeper insights into brain pathology with greater precision and efficiency.”